Journal of Pain and Symptom Management
Volume 43, Issue 2 , Pages 161-171 , February 2012

Mindfulness-Based Stress Reduction for HIV Treatment Side Effects: A Randomized, Wait-List Controlled Trial

Portions of this study were presented by the senior author (M.O.J.) at the New Developments in the Psychology of Illness meeting held in the Yasawa Islands, Fiji in 2009.

  • Larissa G. Duncan, PhD

      Affiliations

    • Osher Center for Integrative Medicine, University of California at San Francisco School of Medicine, San Francisco, California, USA
    • ,
  • Judith Tedlie Moskowitz, PhD, MPH

      Affiliations

    • Osher Center for Integrative Medicine, University of California at San Francisco School of Medicine, San Francisco, California, USA
    • ,
  • Torsten B. Neilands, PhD

      Affiliations

    • Center for AIDS Prevention Studies, University of California at San Francisco School of Medicine, San Francisco, California, USA
    • ,
  • Samantha E. Dilworth, MS

      Affiliations

    • Center for AIDS Prevention Studies, University of California at San Francisco School of Medicine, San Francisco, California, USA
    • ,
  • Frederick M. Hecht, MD

      Affiliations

    • Osher Center for Integrative Medicine, University of California at San Francisco School of Medicine, San Francisco, California, USA
    • ,
  • Mallory O. Johnson, PhD

      Affiliations

    • Center for AIDS Prevention Studies, University of California at San Francisco School of Medicine, San Francisco, California, USA
    • Corresponding Author InformationAddress correspondence to: Mallory O. Johnson, PhD, 50 Beale Street, Suite 1300, San Francisco, CA 94105, USA.

,Accepted 12 April 2011.

References 

  1. Johnson MO, Charlebois E, Morin SF, et al. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage. 2005;29:193–205
  2. Volberding PA. HIV therapy in 2003: consensus and controversy. AIDS. 2003;17:S4–S11
  3. Johnson SC, Gerber JG. Advances in HIV/AIDS therapy. Adv Intern Med. 2000;45:1–40
  4. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS. 2002;16:1201–1215
  5. Chene G, May M, Costagliola D, et al. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration. Paper presented at the XIV International AIDS Conference, Barcelona, Spain: 2002.
  6. Ammassari A, Murri R, Pezzotti P, et al. Self reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445–449
  7. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30:S171–S176
  8. Wills CE, Moore CF. Judgment processes for medication acceptance: self-reports and configural information use. Med Decis Making. 1994;14:137–145
  9. Johnson MO, Chesney MA, Neilands TB, et al. NIMH Healthy Living Project Team. Disparities in reported reasons for not initiating or stopping antiretroviral treatment among a diverse sample of persons living with HIV. J Gen Intern Med. 2009;24:247–251
  10. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985;8:163–190
  11. Kabat-Zinn J, Massion AO, Kristeller J, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry. 1992;149:936–943
  12. Kabat-Zinn J. Full catastrophe living: Using the wisdom of your mind to face stress, pain and illness. New York: Dell Publishing; 1990;
  13. Kabat-Zinn J. Mindfulness-based interventions in context: past, present, and future. Clin Psychol Sci Prac. 2003;10:144–156
  14. Bishop SR. What do we really know about mindfulness-based stress reduction?. Psychosom Med. 2002;64:71–83
  15. Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-based stress reduction and health benefits. A meta-analysis. J Psychosom Res. 2004;57:35–43
  16. Carmody J, Baer RA. Relationships between mindfulness practice and levels of mindfulness, medical and psychological symptoms and well-being in a mindfulness-based stress reduction program. J Behav Med. 2008;31:23–33
  17. Williams KA, Kolar MM, Reger BE, Pearson JC. Evaluation of a wellness-based mindfulness stress reduction intervention: a controlled trial. Am J Health Promot. 2001;15:422–432
  18. Morone NE, Greco CM, Weiner DK. Mindfulness meditation for the treatment of chronic low back pain in older adults: a randomized controlled pilot study. Pain. 2008;134:310–319
  19. Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper U. Mindfulness training as an intervention for fibromyalgia: evidence of postintervention and 3-year follow-up benefits in well-being. Psychother Psychosom. 2007;76:226–233
  20. Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV positive adults on HAART. AIDS Behav. 2003;7:109–117
  21. Lessler JT, Caspar RA, Penne MA, Barker PR. Developing computer assisted interviewing (CAI) for the National Household Survey on Drug Abuse. J Drug Issues. 2000;30:9–34
  22. Gribble JN, Miller HG, Rogers SM, Turner CF. Interview mode and measurement of sexual behaviors: methodological issues. J Sex Res. 1999;36:16–24
  23. Bangsberg DR, Bronstone A, Hofmann R. A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care. 2002;14:3–15
  24. Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS. 2000;11:579–585
  25. Johnson MO, Dilworth SE, Taylor J, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. Ann Behav Med. 2011;41:83–91
  26. Johnson MO, Folkman S. Side effect and disease related symptom representations among HIV+ adults on antiretroviral therapy. Psychology, Health & Medicine. 2004;9:139–148
  27. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255–266
  28. Chesney MA, Ickovics J. Adherence to combination therapy in AIDS clinical trials. Paper presented at Annual Meeting of the AIDS Clinical Trials Group, Washington, DC: 1997.
  29. Hecht FM, Colfax G, Swanson M, Chesney M. Adherence and effectiveness of protease inhibitors in clinical practice [abstract]. Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, 1998; Chicago, IL, Abstract 151.
  30. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30:278–287
  31. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16:269–277
  32. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100–1102
  33. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94
  34. Beck AT. Depression: Causes and treatment. Philadelphia, PA: University of Pennsylvania Press; 1967;
  35. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–396
  36. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063–1070
  37. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006;13:27–45
  38. Vittinghoff E, Glidden D, Shiboski S, McCulloch CE. Regression methods in biostatistics. New York: Springer; 2005;
  39. Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley and Sons; 2002;
  40. Mathews WC, McCutchan JA, Asch S, et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care. 2000;38:750–762
  41. Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage. 1999;18:253–262
  42. Siegel K, Dean L, Schrimshaw EW. Symptom ambiguity among late-middle-aged and older adults with HIV. Res Aging. 1999;21:595–618
  43. Siegel K, Schrimshaw EW, Dean L. Symptom interpretation and medication adherence among late middle-age and older HIV-infected adults. J Health Psychol. 1999;4:247–257
  44. Siegel K, Schrimshaw EW, Dean L. Symptom interpretation: implications for delay in HIV testing and care among HIV-infected late middle-aged and older adults. AIDS Care. 1999;11:525–535
  45. Klatt MD, Buckworth J, Malarkey WB. Effects of low-dose mindfulness-based stress reduction (MBSR-ld) on working adults. Health Educ Behav. 2009;36:601–614

PII: S0885-3924(11)00370-8

doi: 10.1016/j.jpainsymman.2011.04.007

Journal of Pain and Symptom Management
Volume 43, Issue 2 , Pages 161-171 , February 2012

Article Tools

* Image Usage & Resolution